Data-driven modeling of Alzheimer Disease pathogenesis

Journal of Theoretical Biology

Volumn 290, Issue 1, 2011, Pages 60-72

  Anastasio, Thomas J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Biological regulation; Complex systems; Model checking; Neurological disease; Term rewriting

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CASPASE 3; HYPOXIA INDUCIBLE FACTOR;

COMPUTER SIMULATION; DISEASE; NEUROLOGY; PATHOGEN;

ALZHEIMER DISEASE; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COMPUTER LANGUAGE; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER SIMULATION; INFORMATION PROCESSING; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; MODELS, NEUROLOGICAL;

EID: 80053362041     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.08.038     Document Type: Article

References (75)

1. Arun G.K., Gemma S., Tang J. Beta-secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2008, 5:399-408.
2. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.-M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate AΒ1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
3. Bodles A.M., Barger S.W. Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiology of Aging 2005, 26:9-16.
4. Bulgarelli I., Tamiazzo L., Bresciani E., Rapetti D., Caporali S., Lattuada D., Locatelli V., Torsello A. Desacyl-ghrelin and synthetic GH-secretagogus modulate the production of inflammatory cyotkines in mouse microglia cells stimulated by beta-amyloid fibrils. Journal of Neuroscience Research 2009, 87:2718-2727.
5. Bader Lange M.L., Clair D., Markesbery W.R., Studzinki C.M., Murphey M.P., Butterfield D.A. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh)×PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiology of Disease 2010, 38:104-115.
6. Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., Miano J.M., Zlokovic B.V. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nature Cell Biology 2009, 11(143):153.
7. Clavel M., Durán R., Eker S., Lincoln P., Martí-Oliet N., Meseguer J., Talcott C. All About Maude - A High-Performance Logical Framework: How to Specify, Program, and Verify Systems in Rewriting Logic. (Lecture Notes in Computer Science 4350) 2007, Springer, Berlin.
8. Cole S.L., Vassar R. The basic biology of BACE1: a key therapeutic target for Alzheimer's disease. Current Genomics 2007, 8:509-530.
9. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Medicine 2010, 12:1-12.
10. Citron M. Alzheimer's disease: strategies for disease modification. Nature Reviews Drug Discovery 2010, 9:387-398.
11. Chow N., Bell R.D., Deane R., Streb J.W., Chen J., Brooks A., Van Nostrand W., Miano J.M., Zlokovic B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proceedings of the National Academy of Sciences 2007, 104:823-828.
12. Di Carlo M. Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. European Biophysical Journal 2010, 39:877-888.
13. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 2003, 38:9-12.
14. Deane R., Wu Z., Sagare A., Davis J., Yan S.D., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., Zlokovic B.V. LRP/amyloid Β-peptide interaction mediates differential brain efflux of AΒ isoforms. Neuron 2004, 43:333-344.
15. Deane R., Yan S.D., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B.V. RAGE mediates amyloid-Β peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine 2003, 9:907-913.
16. Dave J.R., Williams A.J., Moffett J.R., Koenig M.L., Tortella F.C. Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists. Neurotoxicity Research 2003, 5:255-264.
17. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Reviews Neurology 2010, 6:99-107.
18. de la Torre J.C. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. International Review of Neurobiology 2009, 84:35-48.
19. Eker S., Knapp M., Laderoute K., Lincoln P., Talcott C. Pathway logic: executable models of biological networks. Electronic Notes in Theoretical Computer Science 2002, http://www.elsevier.nl/locate/entcs/volume71.html.
20. Fisher J., Henzinger T.A. Executable cell biology. Nature Biotechnology 2007, 25:1239-1249.
21. Faghihi M.A., Modarresi F., Khalil A.M., Wood D.E., Sahagan B.G., Morgan T.E., Finch C.E., Laurent I.I.I.G., Kenny P.J., Wahlestedt C. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nature Medicine 2008, 14:723-730.
22. George-Hyslop P., Petit A. Molecular biology and genetics of Alzheimer's disease. Comptes Rendus Biologies 2004, 328:119-130.
23. Guglielmotto M., Aragno M., Autelli R., Gilliberto L., Novo E., Collombatto S., Danni O., Parola M., Smith M.A., Perry G., Tamagno E., Tabaton M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. Journal of Neurochemistry 2009, 108:1045-1056.
24. Hlavacek W.S., Raeder J.R., Blinow M.L., Posner R.G., Hucka M., Fontana W. Rules for modeling signal-transduction systems. Science's stke 2006, http://stke.sciencemag.org/cgi/content/full/sigtrans;2006/344/re6.
25. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
26. He W., Lu Y., Qahwash I., Hu X.-Y., Chang A., Yan R. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nature Medicine 2004, 10:959-965.
27. Hiltunen M., Mäkinen P., Peräniemi S., Sivenius J., van Groen T., Soininen H., Jolkkonen J. Focal cerebral ischemia in rats alters APP processing and expression of Abeta peptide degrading enzymes in the thalamus. Neurobiology of Disease 2009, 35:103-113.
28. Harris-White M.E., Frautschy S.A. Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and Cognition. Current Drug Targets-CNS & Neurological Disorders 2005, 4:469-480.
29. Imbimbo B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Current Topics in Medicinal Chemistry 2008, 8:54-61.
30. Iqbal K., Wang X., Blanchard J., Liu F., Gong C.X., Grundke-Iqbal I. Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochemical Society Transactions 2010, 38:962-969.
31. Klamt S., Saez-Rodriguez J., Lindquist J., Simeoni L., Gilles E.D. A methodology for the structural and functional analysis of signaling and regulatory networks. BMC Bioinformatics 2006, 7:56.
32. Klamt S., Saez-Rodriguez J., Gilles E.D. Structural and functional analysis of cellular networks with CellNetAnalyzer. BMC Systems Biology 2007, 1:2.
33. Kim S.-K., Park H.-J., Hong H.S., Baik E.J., Jung M.W., Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. The FASEB Journal 2006, 20:157-159.
34. Kume H., Konishi Y., Murayama K.S., Kametani F., Araki W. Expression of reticulon 3 in Alzheimer's disease brain. Neuropathology and Applied Neuropathology 2009, 35:178-188.
35. Kanekiyo T., Bu G. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. The Journal of Biological Chemistry 2009, 284:33352-33359.
36. Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neuroscience Letters 2003, 350:113-116.
37. Lakshmana M.K., Chen E., Yoon I.-S., Kang D.E. C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. Journal of Cellular and Molecular Medicine 2008, 12:2665-2674.
38. LeBlanc M.H., Huang M., Patel D., Smith E.E., Devidas M. Glucose given after hypoxic ischemia does not affect brain injury in piglets. Stroke 1994, 25:1443-1447.
39. Lue L.F., Kuo Y.M., Beach T., Walker D.G. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Molecular Neurobiology 2010, 41:115-128.
40. Mainzer K. Thinking in Complexity: The Computational Dynamics of Matter, Mind, and Mankind, Fifth Edition 2007, Springer-Verlag, Heidelberg.
41. Muhammad A., Flores I., Zhang H., Yu R., Staniszewski A., Planel E., Herman M., Ho L., Kreber R., Honig L.S., Ganetzky B., Duff K., Arancio O., Small S.A. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and A-beta accumulation. Proceedings of the National Academy of Science USA 2008, 105:7327-7332.
42. Manelli A.M., Stine W.B., Van Eldik L.J., LaDu M.J. ApoE and Abeta-42 interactions: effects of isoform and conformation on structure and function. Journal of Molecular Neuroscience 2004, 23:235-246.
43. Minopoli G., Passaro F., Aloia L., Carolmagno F., Melillo R.M., Santoro M., Forzati F., Zambrano N., Russo T. Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precurson protein: role of the low-density lipoprotein receptor-related protein. Neuro-degenerative Diseases 2007, 4:94-100.
44. O' Connor T., Sadleir K.R., Maus E., Velliquette R.A., Zhou J., Cole S.L., Eimer W.A., Hitt B., Bembinster L.A., Lammich S., Lichtenthaler S.F., Hébert S.S., De Strooper B., Haass C., Bennett D.A., Vassar R. Phosphorylation of the translation initiation factor e1F2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008, 60:988-1009.
45. Oda S., Oda T., Takabuchi S., Nishi K., Wakamatsu T., Tanaka T., Adachi T., Fukuda K., Nohara R., Hirota K. The calcium channel blocker cilnidipine selectively suppresses hypoxia-inducible factor 1 activity in vascular cells. European Journal of Pharmacology 2009, 606:130-136.
46. Pietrzik C.U., Busse T., Merriam D.E., Weggen S., Koo E.H. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO Journal 2002, 21:5691-5700.
47. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 2001, 81:741-766.
48. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proceedings of the National Academy of Science of the United States of America 2006, 103:443-448.
49. Sarajärvi T., Haapasalo A., Viswanathan J., Mäkinen P., Laitinen M., Soininen H., Hiltunen M. Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. The Journal of Biological Chemistry 2009, 284:34433-34443.
50. Small S.A. Retromer sorting: a pathological pathway in late-onset Alzheimer disease. Archives of Neurology 2008, 65:323-328.
51. Scheibel A.B., Duong T.H., Jacobs R. Alzheimer's disease as a capillary dementia. Annals of Medicine 1989, 21:103-107.
52. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.-M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Boldgaber D., Roese A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of the National Academy of Sciences 1993, 90:8098-8102.
53. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Fragnione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 2000, 106:1489-1499.
54. Scholefield Z., Yates E.A., Wayne G., Amour A., McDowell W., Turnbull J.E. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's Beta-secretase. The Journal of Cell Biology 2003, 163:97-107.
55. Sudoh S., Frosch M.P., Wolf B.A. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002, 41:1090-1099.
56. Saunders A.M. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analysis. Journal of Neuropathology and Experimental Neurology 2000, 59:751-758.
57. Sims-Robinson C., Kim B., Rosko A., Feldman E.L. How does diabetes accelerate Alzheimer disease pathology?. Nature Reviews Neuroscience 2010, 6:551-559.
58. Thomas R., D'Ari R. Biological Feedback 1990, CRC Press, Boca Raton.
59. Talcott C. Pathway logic. Lecture Notes in Computer Science 2008, 5016:21-53.
60. Tamagno E., Guglielmotto M., Aragno M., Borghi R., Autelli R., Giliberto L., Muraca G., Danni O., Zhu X., Smith M.A., Perry G., Jo D.G., Mattson M.P., Tabaton M. Oxidative stress activates a positive feedback between the gamma and beta secretase cleavages of the beta-amyloid precursor protein. Journal of Neurochemistry 2008, 104:683-695.
61. Tamagno E., Guglielmotto M., Giliberto L., Vitali A., Borghi R., Autelli R., Danni O., Tabaton M. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiology of Aging 2009, 30:1563-1573.
62. Tesco G., Koh Y.H., Kang E.L., Cameron A.N., Das S., Sena-Esteves M., Hiltunen M., Yang S.H., Zhoung Z., Shen Y., Simpkins J.W., Tanzi R.E. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007, 54:721-737.
63. Thal D.R., Griffin W.S., de Vos R.A., Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathology 2008, 115:599-609.
64. Udan M.L.D., Ajit D., Crouse N.R., Nichols M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. Journal of Neurochemistry 2008, 104:524-533.
65. Ulery P.G., Beers J., Mikhailenko I., Tanzi R.E., Rebeck GW, Hyman BT, Strickland DK Modulation of beta-amyloid precurson protein processing by the low density lipoprotien receptor-related protein (LRP): evidence that LRP contributes to the pathogenesis of Alzheimer's disease. Journal of Biological Chemistry 2000, 275:7410-7415.
66. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Leoloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.-C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precurson protein by the transmembrate aspartic protease BACE. Science 1999, 286:735-741.
67. Vassar R., Kovacs D.M., Yan R., Wong P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. The Journal of Neuroscience 2009, 29:12787-12794.
68. Walsh D.M., Selkoe D.J. A beta oligomers-a decade of discovery. Journal of Neurochemistry 2007, 101:1172-1184.
69. Wang W.-X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., Nelson P.T. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. Journal of Neuroscience 2008, 28:1213-1223.
70. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Cancer genome project: mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
71. Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A., Liu D., Li F., Armstrong D., Gasiewicz T., Zidovetzki R., Song X., Hofman F., Zlokovic B.V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nature Medicine 2005, 11:959-965.
72. Xia S., Tai X., Wang Y., An X., Qian G., Dong J., Wang X., Sha B., Wang D., Murthi P., Kalionis B., Wang X., Bai C. Involvement of Gax gene in hypoxia-induced pulmonary hypertension, proliferation, and apoptosis of arterial smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology 2011, 44:66-73.
73. Yoon I.-S., Chen E., Busse T., Repetto E., Lakshmana M.K., Koo E.H., Kang D.E. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. The FASEB Journal 2007, 21:2742-2752.
74. Yang D.S., Small D.H., Seydel U., Smith J.D., Hallmayer J., Gandy S.E., Martins R.N. Apoliprotien E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 1999, 90:1217-1226.
75. Zhang X., Zhou K., Wang R., Cui J., Lipton S.A., Liao F.-F., Xu H., Zhang Y. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. Journal of Biological Chemistry 2007, 282:10873-10880.